Mallinckrodt is “suspending” its plan to spin off its specialty generics business, which includes oxycodone and hydrocodone, into a separate company amid market nervousness about the proposed standalone firm’s exposure to potentially big opioid lawsuit payouts.
Mallinckrodt Delays Generics Spinoff
Mallinckrodt has put on hold its plan to spin off its specialty generics business due to investor worries about potentially big payouts arising from ongoing US opioids litigation.
